Literature DB >> 19825812

Prognostic value of peak and post-exercise treadmill exercise echocardiography in patients with known or suspected coronary artery disease.

Jesús Peteiro1, Alberto Bouzas-Mosquera, Francisco J Broullón, Ana Garcia-Campos, Pablo Pazos, Alfonso Castro-Beiras.   

Abstract

AIMS: Although peak may have higher sensitivity than post-treadmill exercise echocardiography (EE) for the detection of coronary artery disease (CAD), its prognostic value remains unknown. We sought to assess the relative values of peak and post-EE for predicting outcome in patients with known/suspected CAD. METHODS AND
RESULTS: We studied 2947 patients who underwent EE. Wall motion score index (WMSI) was evaluated at rest, peak, and post-exercise. Ischaemia was defined as the development of new or worsening wall motion abnormalities with exercise. Separate analyses for all-cause mortality and major cardiac events (MACE) were performed. Ischaemia developed in 544 patients (18.5%). Among them, ischaemia was detected only at peak exercise in 124 patients (23%), whereas 414 (76%) had ischaemia at peak plus post-exercise imaging and six patients (1%) had ischaemia only at post-exercise. During follow-up, 164 patients died. The 5-year mortality rate was 3.5% in patients without ischaemia, 15.3% in patients with peak ischaemia alone, and 14% in patients with post-exercise ischaemia (P < 0.001 normal vs. ischaemic groups). In the multivariate analysis, post-exercise WMSI was an independent predictor of MACE [hazard ratio (HR) 1.87, 95% confidence interval (CI) 1.09-2.19, P = 0.02]. Peak exercise WMSI was an independent predictor of MACE (HR 2.19, 95% CI 1.30-3.69, P = 0.003) and mortality (HR 1.58, 95% CI 1.07-2.35, P = 0.02). The addition of peak EE results to clinical, resting echocardiography, exercise variables, and post-EE provided incremental prognostic information for MACE (P = 0.04) and mortality (P = 0.04).
CONCLUSION: Peak treadmill EE provides significant incremental information over post-EE for predicting outcome in patients with known or suspected CAD.

Entities:  

Mesh:

Year:  2009        PMID: 19825812     DOI: 10.1093/eurheartj/ehp427

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Exercise echocardiography.

Authors:  Jesus Peteiro; Alberto Bouzas-Mosquera
Journal:  World J Cardiol       Date:  2010-08-26

2.  Left ventricular torsion and circumferential strain responses to exercise in patients with ischemic coronary artery disease.

Authors:  Jesus Peteiro; Alberto Bouzas-Mosquera; Javier Broullon; Gabriel Sanchez-Fernandez; Cayetana Barbeito; Lucia Perez-Cebey; Dolores Martinez; Jose M Vazquez-Rodriguez
Journal:  Int J Cardiovasc Imaging       Date:  2016-09-19       Impact factor: 2.357

Review 3.  Exercise cardiovascular magnetic resonance: development, current utility and future applications.

Authors:  Thomas P Craven; Connie W Tsao; Andre La Gerche; Orlando P Simonetti; John P Greenwood
Journal:  J Cardiovasc Magn Reson       Date:  2020-09-10       Impact factor: 5.364

4.  Comparison of 5-Year Outcomes for Patients With Coronary Artery Disease in Groups With and Without Revascularization With Different Results of Stress Echocardiography.

Authors:  Angela Zagatina; Ludmila Krylova; Yuliya Vareldzhan; Tatyana V Tyurina; Olga Clitsenko; Nadezhda Zhuravskaya
Journal:  Cardiol Res       Date:  2013-10-15

Review 5.  Exercise stress echocardiography: Where are we now?

Authors:  Carlos Alberto Cotrim; Hugo Café; Isabel João; Nuno Cotrim; Jorge Guardado; Pedro Cordeiro; Hortense Cotrim; Luis Baquero
Journal:  World J Cardiol       Date:  2022-02-26

6.  Clinical applications of exercise stress echocardiography in the treadmill with upright evaluation during and after exercise.

Authors:  Carlos Cotrim; Isabel João; Paula Fazendas; Ana R Almeida; Luís Lopes; Bruno Stuart; Inês Cruz; Daniel Caldeira; Maria José Loureiro; Gonçalo Morgado; Hélder Pereira
Journal:  Cardiovasc Ultrasound       Date:  2013-07-22       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.